Browsing Schizophrenia and Psychotic Disorders by Title
Now showing items 24-43 of 74
-
The Early Youth Engagement in first episode psychosis (EYE-2) study: pragmatic cluster randomised controlled trial of implementation, effectiveness and cost-effectiveness of a team-based motivational engagement intervention to improve engagement
(2021-04)Background Early Intervention in Psychosis (EIP) services improve health outcomes for young people with psychosis in the medium–long term, but 25% of young people disengage in the first 12 months with costs to their mental ... -
The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study
(2019)One of the most statistically significant loci to result from large-scale GWAS of schizophrenia is 10q24.32. However, it is still unclear how this locus is involved in the pathoaetiology of schizophrenia. The hypothesis ... -
Effect of point of care blood testing on physical health check completion in mental health services: mixed-methods evaluation
(2020-10)Physical health outcomes in severe mental illness are worse than in the general population. Routine physical health check completion in this group is poor. Aims To quantitatively and qualitatively evaluate the impact of ... -
Effects of SlowMo, a Blended Digital Therapy Targeting Reasoning, on Paranoia Among People With Psychosis A Randomized Clinical Trial
(2021-04)IMPORTANCE Persistent paranoia is common among patients with psychosis. Cognitive-behavioral therapy for psychosis can be effective. However, challenges in engagement and effectiveness remain. OBJECTIVE To investigate ... -
Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis
(2018-06-12)Background: Attenuated positive psychotic symptoms represent the defining features of the clinical high-risk for psychosis (CHR-P) criteria. The effectiveness of each available treatment for reducing attenuated positive ... -
Elevated homocysteine and N-methyl-D-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome
(2017-12)A 19-year-old male with 22q11.2 deletion syndrome presented with a 4-year history of cognitive decline and symptoms suggestive of atypical psychosis. Potential for elevated homocysteine and NMDA-receptor antibodies in the ... -
Evidence base for early intervention in psychosis services in rural areas: A critical review
(2020-07)Aim: Early Intervention in Psychosis teams (EITs) are a growing entity internationally, yet they remain under-researched given challenges facing their delivery. Model adaptations include stand-alone services, a hub-and-spoke ... -
Examination of the neural basis of psychotic-like experiences in adolescence during processing of emotional faces
(2020-03)Contemporary theories propose that dysregulation of emotional perception is involved in the aetiology of psychosis. 298 healthy adolescents were assessed at age 14- and 19-years using fMRI while performing a facial emotion ... -
Excessive sleepiness in patients with psychosis: An initial investigation
(2021-01)Clinical experience indicates that excessive sleepiness and hypersomnia may be a common issue for patients with psychosis. Excessive sleepiness is typically ascribed to the sedating effects of antipsychotic medications but ... -
The Experience of Sleep Problems and Their Treatment in Young People at Ultra-High Risk of Psychosis: A Thematic Analysis
(2018-08)We view sleep disruption as a contributory causal factor in the development of psychotic experiences. Clinical trials indicate that psychological interventions targeting insomnia result in improvements in both sleep and ... -
Fear of illness recurrence and mental healthanxiety in people recovering from psychosis andcommon mental health problems
(2020-06)Objectives: It is well known that mental health problems can recur even after effective treatment, leading to an understandable fear of illness recurrence (FIR) and mental health anxiety (MHA). These may themselves contribute ... -
Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something
(2019-05-03)Since its first description in 1863, ‘hebephrenia’ has highlighted a group of patients characterised by an early onset of illness, formal thought disorder, bizarre behaviour and incongruent emotional expression. A proportion ... -
Hemizygous mutations in L1CAM in two unrelated male probands with childhood onset psychosis
(2020-06)Objective :To identify genes underlying childhood onset psychosis. Methods :Patients with onset of psychosis at age 13 or younger were identified from clinics across England, and they and their parents were exome sequenced ... -
How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices
(2021-08)Background The magnitude of the superiority of antipsychotics over placebo is debated. One reason is that the effect-size index which is usually used in meta-analyses is in standard deviation units. Many other indices, ... -
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis
(2019-06)Introduction: In patients with schizophrenia, medication adherence is important for relapse prevention, and effective adherence monitoring is essential for treatment planning. A digital medicine system (DMS) has been ... -
‘If he feels better I'll feel better’ relationships with individuals at high-risk of developing psychosis
(2021-03)A large proportion of individuals with an at-risk mental state (ARMS) live at home and are supported by their families. Recommended treatment includes family intervention (FI), and therefore, understanding relationships ... -
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
(2019-07)Importance: Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether ... -
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
(2019-06)Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ... -
Is there a choice to make? A pilot study investigating attitudes towards treatment in an Early Intervention for Psychosis service
(2018-03)Purpose The purpose of this paper is to investigate health care professionals’ (HCPs) and service-users’ (SUs) attitudes towards different treatment options in an Early Intervention for Psychosis (EIP) service as well as ...
